A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in
comparison to docetaxel for the treatment of unresectable non-small cell lung cancer
Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Cisplatin
in Patients with Advanced Solid Tumors to determine the recommended dose (RD) of PM01183 in
combination with cisplatin, to characterize the safety profile, the pharmacokinetics (PK) of
this combination, to obtain preliminary information on the clinical antitumor activity and
to conduct an exploratory pharmacogenomic (PGx) analysis.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.